- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GSK to donate 50 million pandemic vaccines
21 May 2009
GlaxoSmithKline (GSK) has offered to donate 50 million doses of a pandemic vaccine to the World Health Organisation in the event of a global flu outbreak.
The offer was made during a meeting between UN officials, vaccine makers and othre health experts to discuss how to provide vaccines to poor countries if the swine flu outbreak goes global.
No pandemic vaccine exists yet, byt pharma companies claim they can begin production immediately once they get the vaccine's key ingredient, a 'seed stock' based on the virus. That is being developed by the Unites States's Centers for Disease Prevention and Control and should be available by mid-July.
GSK has already signed agreements with various countries to provide them with pandemic vaccine as soon as it becomes available. These include the UK, Belgium and Finland.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
